Key Details
Price
$5.07Annual ROE
5.62%Beta
1.53Events Calendar
Next earnings date:
Mar 7, 2025Recent quarterly earnings:
Oct 30, 2024Recent annual earnings:
Mar 7, 2024Next ex-dividend date:
N/ARecent ex-dividend date:
N/ANext split:
N/ARecent split:
N/AAnalyst ratings
Recent major analysts updates
Market Data
Price
Market cap
Technical
Dividend
Profitability
Revenue
Profit
EPS
ROA & ROE
EBIT & EBITDA
Valuation
PE Ratio
PB Ratio
PS Ratio
Enterprise value
EV/EBITDA
Financial Health
Liquidity
Leverage
Risk & Stability
Balance Sheet
Assets
Equity
Liabilities
Debt
Expenses
Cash Flow
Cashflow Activities
Free CashFlow
CAPEX
Institutional Ownership
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Custom Truck One Source: My Downgrade To Buy Reflects State Of Demand
Phase 1/2 data showed a median overall survival ("mOS") of 21.3 months versus a synthetic control of 6.7 months, an increase in T-cell activation, and favorable safety profile for patients receiving INT230-6 alone INVINCIBLE-3 Study is recruiting and expected to enroll 333 patients with leiomyosarcoma, liposarcoma and undeferential pleomorphic sarcoma; authorizations for the INVINCIBLE-3 Study have been received in the U.S., Canada, Europe and Australia SHELTON, Conn. , Nov. 18, 2024 /PRNewswire/ -- Intensity Therapeutics, Inc. (Nasdaq: INTS), ("Intensity" or "the Company") a late-stage clinical biotechnology company focused on the discovery and development of proprietary, novel immune-based intratumoral cancer therapies designed to kill tumors and increase immune system recognition of cancers, today announced that Christian F.
– Long-term follow-up data highlight further reductions in tumor size, increase in ORR with additional CRs, sustained improvement in desmoid tumor symptoms, and consistent safety profile, now with a median duration of therapy of approximately 3 years –
Custom Truck One Source, Inc. (CTOS) came out with a quarterly loss of $0.07 per share versus the Zacks Consensus Estimate of a loss of $0.03. This compares to earnings of $0.04 per share a year ago.
Custom Truck One Source, Inc. (NYSE:CTOS ) Q2 2024 Earnings Conference Call August 2, 2024 5:00 PM ET Company Participants Brian Perman - VP, IR Ryan McMonagle - CEO Chris Eperjesy - CFO Conference Call Participants Justin Hauke - Robert W. Baird Tami Zakaria - JPMorgan Michael Shlisky - D.A.
Custom Truck One Source, Inc. (CTOS) came out with a quarterly loss of $0.10 per share versus the Zacks Consensus Estimate of a loss of $0.01. This compares to earnings of $0.05 per share a year ago.
Custom Truck One Source (CTOS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Custom Truck One Source, Inc. (CTOS) reported a quarterly loss of $0.06 per share, which was higher than the expected loss of $0.01 per share according to the Zacks Consensus Estimate. This is a decrease from earnings of $0.06 per share in the same quarter last year.
Custom Truck One Source, Inc. (CTOS) came out with quarterly earnings of $0.07 per share, missing the Zacks Consensus Estimate of $0.11 per share. This compares to earnings of $0.15 per share a year ago.
FAQ
- What is the ticker symbol for Custom Truck One Source?
- Does Custom Truck One Source pay dividends?
- What sector is Custom Truck One Source in?
- What industry is Custom Truck One Source in?
- What country is Custom Truck One Source based in?
- When did Custom Truck One Source go public?
- Is Custom Truck One Source in the S&P 500?
- Is Custom Truck One Source in the NASDAQ 100?
- Is Custom Truck One Source in the Dow Jones?
- When was Custom Truck One Source's last earnings report?
- When does Custom Truck One Source report earnings?
- Should I buy Custom Truck One Source stock now?